Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04965090
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
- NCT04965090 ↗
- Completed
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on NCT04965090 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04965090 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Non Small Cell Lung Cancer; Recurrent Non Small Cell Lung Cancer
- Interventions
- Amivantamab; Lazertinib
- Arms
- Patients with parenchymal brain metastases · Experimental
- Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases · Experimental
- Enrollment
- 43
- Primary outcomes
- CNS overall response rate (ORR) (Cohort 1)
- measure CNS overall response rate (ORR) (Cohort 2)
- Sponsor
- Memorial Sloan Kettering Cancer Center with Janssen Scientific Affairs, LLC
- Start
- Sep 30, 2021
- Primary completion
- Dec 15, 2025
- Results posted
- No
- Registry record
- NCT04965090 · updated Dec 18, 2025
Publications
linked from the registry- Chen MF, Lee JJ, Choudhury NJ, Hui AB, Jeng MY, Zheng J, Aly RG, Sielski N, Ahn L, Pupo A, Nesselbush MC, Jabara I, Wilcox JA, Santomasso BD, Lin AL, Schaff L, Chaft JE, Riely GJ, Kris MG, Arfe A, Yang SR, Young RJ, Diehn M, Boire A, Yu HA. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 Mar;21(3):103505. doi: 10.1016/j.jtho.2025.10.012. Epub 2025 Oct 23. PubMed 41139066